期刊文献+

Targeted therapies in gynecological cancers:a comprehensive review of clinical evidence 被引量:2

原文传递
导出
摘要 Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment.The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies,which are emerging as groundbreaking and promising cancer treatment strategies.In gynecologic malignancies,potential therapeutic targeted agents include antiangiogenic agents,poly(ADP-ribose)polymerase(PARP)inhibitors,tumor-intrinsic signaling pathway inhibitors,selective estrogen receptor downregulators,and immune checkpoint inhibitors.In this article,we provide a comprehensive review of the clinical evidence of targeted agents in gynecological cancers and discuss the future implication.
出处 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2020年第1期1261-1294,共34页 信号转导与靶向治疗(英文)
基金 supported by National Major Scientific and Technological Project for“Significant New Drugs Development”in China(2018ZX09733001).
  • 相关文献

参考文献3

二级参考文献163

  • 1Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011,474:609-615.
  • 2Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer, 2010,10:803-808.
  • 3Kurman RJ, Shih leM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol, 2011,42:918-931.
  • 4Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov, 2012,2:401-404.
  • 5Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal,2013,6:pI1.
  • 6Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res, 2005,11 :6422-6430.
  • 7Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene, 2005,24:7455-7464.
  • 8Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 2009,9:550-562.
  • 9Leary A, Lhomme C, Auclin E, et al. The PI3K/Akt/mTOR pathway in ovarian cancer: biological rationale and therapeutic promise. INTECH Open Access Publisher, 2013.
  • 10Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle, 2003,2:339-345.

共引文献203

同被引文献3

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部